Pressmeddelande

BioStock: DanCann Pharma towards commercialisation with rights issue

Cision Publicerad: 31 Oct 2022 08:14

For DanCann, the aim is clear – to give patients who lack treatment options a better life through medical cannabis and cannabinoids. After building a solid portfolio of products, the next step for the Danish pharma company is commercialisation. In order to take this step, the company is now conducting a rights issue that, if fully subscribed, can raise 28.5 million DKK. BioStock talked to CEO Jeppe Krog Rasmussen to find out more.

Read the full interview with Jeppe Krog Rasmussen at biostock.se:

https://www.biostock.se/en/2022/10/dancann-pharma-towards-commercialisation-with-rights-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Nyheter om Dancann Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!